Stay updated on SB12 Pharmacokinetics Safety in Healthy Subjects Clinical Trial

Sign up to get notified when there's something new on the SB12 Pharmacokinetics Safety in Healthy Subjects Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SB12 Pharmacokinetics Safety in Healthy Subjects Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:38:26.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the pharmacokinetic, safety, tolerability, immunogenicity, and pharmacodynamic study of SB12, EU sourced Soliris, and US sourced Soliris in healthy subjects.
    Difference
    0.1%
    Check dated 2024-06-06T14:46:14.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, such as specific health conditions and prior treatments. The new criteria specify requirements like body weight, body mass index, blood pressure, and other health-related factors.
    Difference
    39%
    Check dated 2024-05-22T21:29:17.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1%
    Check dated 2024-04-30T22:33:57.000Z thumbnail image

Stay in the know with updates to SB12 Pharmacokinetics Safety in Healthy Subjects Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SB12 Pharmacokinetics Safety in Healthy Subjects Clinical Trial page.